Pazopanib (Votrient) | CancerIndex
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma - Clinical Genitourinary Cancer
Votrient 400 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc)
Hopes and failures in front-line ovarian cancer therapy - ScienceDirect
Overall Survival and Progression-free Survival among IMDC... | Download Scientific Diagram
Overall survival in leiomyosarcoma patients. | Download Scientific Diagram
Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review - Chen - Translational Cancer Research
Frontiers | Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials - The Lancet Oncology
Full article: Pazopanib for the treatment of soft-tissue sarcoma
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet Oncology
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis | BMC Cancer | Full Text
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort - Mustafa Karaağaç, Yasin Sezgin, Melek Karakurt Eryılmaz, Murat Araz, Muhammet Ali
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
![PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/343485ee055845a60e57da69b711a4ea3bb2d505/4-Figure2-1.png "PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar")
PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar
Clinical Trials | VOTRIENT® (pazopanib) tablets
Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma | Cell Death Discovery
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma | BMC Cancer | Full Text
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
